Release of New FDA Guidance Declines Sharply Following Trump’s Inauguration
[...] Rachel Sachs, an associate professor of law at Washington University in St. Louis, told Focus: “I think they're waiting for Gottlieb to set his priorities, and they'll move forward then. The other thing I'll say is that they've been busy behind the scenes on things like the -UFAs [user fee agreements], so I wouldn't be surprised if a lot of time has gone into that.”
Read the full article here.
Read the Full Article
Tags
bioethics fda health law policy pharmaceuticals public health rachel sachs regulation